rolipram has been researched along with Koch's Disease in 1 studies
Excerpt | Relevance | Reference |
---|---|---|
"We analyzed the time to death in Mycobacterium tuberculosis-infected mice receiving type 4 PDE-Is (rolipram and cilomilast) and the impact on bacterial burden, time to clearance, and relapse when types 3 and 5 PDE-Is (cilostazol and sildenafil, respectively) and rolipram were added to the standard treatment." | 3.79 | Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. ( Ammerman, NC; Bishai, WR; Maiga, M; Maiga, MC; Murphy, R; Polis, M; Siddiqui, S; Tounkara, A, 2013) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Maiga, M | 1 |
Ammerman, NC | 1 |
Maiga, MC | 1 |
Tounkara, A | 1 |
Siddiqui, S | 1 |
Polis, M | 1 |
Murphy, R | 1 |
Bishai, WR | 1 |
1 other study available for rolipram and Koch's Disease
Article | Year |
---|---|
Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment.
Topics: Animals; Antitubercular Agents; Bacterial Load; Cilostazol; Disease Models, Animal; Drug Interaction | 2013 |